Short-term omalizumab as a potential rescue therapy for alopecia areata flares during Janus kinase inhibitor maintenance

Read full text Summarise with VIRAT
Authors: Qin Wang, Ke Cheng, Jui‐Ming Lin, Ke Tao, Minghuan Xu, Xinyi Zhang, Sichong Tang, Chunya Ni, Wenyu Wu, JINRAN LIN
Cited by: 0
References: 5

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

To the Editor: Alopecia areata (AA) is a chronic autoimmune disease for which oral Janus kinase (JAK) inhibitors have demonstrated robust and generally well-tolerated efficacy. However, long-term control is not fully durable, and flares can occur even in initial responders who remain on therapy.1,2 Despite this, the clinical profile of patients prone to such flares and effective management strategies remain unclear. In patients with an allergic background, therapies targeting Th2/allergic pathways have been associated with reduced relapse.

Fields of Study & Subjects

Hair Growth and Disorders Dermatology and Skin Diseases melanin and skin pigmentation

Publication details

Journal / source
JAAD International
Volume
26
Pages
60–62
Publication date
23 March 2026
Language
EN